Tuesday, April 2, 2019

Repurposing as a Future Strategy for Pharmaceutical Research

Repurposing as a Future Strategy for pharmaceutical ResearchWith the urgent need for bracing treatments for serious diseases and concerns about otherwise existing unmet patient needs as healthy as the equal of traditional medicate discovery and other productivity issues on the uninterrupted increase, dose repurposing has become an attractive alternative. dose repurposing is defined as the act of discovering overb elderly indications for existing drug compounds (Tari and Patel, 2014). Tari Patel (2014) further explain that the concept goat drug repurposing is that novel drug indications fuel be identified ground on the principle that a primary drug target can be associated with diseases other than its original drug indication. Various systematic approaches direct been proposed for finding new indications for drugs some of this include discovering drugs hat share a significant deem of side effects as they may sacrifice similar actions and those with similar chemical compounds. The most cited success for drug shift is sildenafil, a drug veritable by Pfizer and originally indicated for the treatment of angina pectoris but was discovered to show an improvement in patients suffering from erect dysfunction as well (Pantziarka et al, 2014) onlineDrug repurposing is becoming the surest way to both provide treatment for both new and old diseases, as well as reducing greatly the cost of production of these treatments. Persidis (2011) online lists a equalise of advantages crediting this, some of which include that pre-existing drugs or those which have been proven to be safe at late-stage trials greatly reduce victimization risk notwithstanding when repurposed for potentially new indications. The article continues to add that there is a extensive money saving advantage when comparing launching a repurposed drug into the market with launching a completely new formulation to pharmaceutical companies owning original use rights to the drug. On the othe r hand, NCBI refers that as drugs are just now approved for specific therapeutic indications within clear natural rubber boundaries and afterward intense investigation, finding new drug-target interactions is most often hampered by safety issues regarding dosage and delivery capability as discovery of a repurposed drug working within the approved therapeutic window is a elevated occurrence suggesting also that even in a case where arrogate formulations and delivery devices were available to eliminate the problems associated with dosage and delivery within the get therapeutic window, the issue of lack of integration with pharmaceutical and toxicological sciences facilitate persists. These go without including the problems associated with protection of intellectual property as various new drug-target-disease triplets are often disclosed by various online databases. Repositioned drugs have been a huge success in providing effective remedies for a large number of patients suffer ing from a wide range of diseases, have promised to deliver new treatments for even more diseases including some of the most perverse diseases the plague the substitution nervous system, cardio-vascular system, many metabolic disorders and cancer. Precisely, the scope of drug repurposing can be widened in future to cater for the development of drugs with multiple targets as in the area of oncology and those which target disease in various ways as in obesity. It can even more importantly create opportunities for the development of second-generation drugs (Sehkon, 2013) Therefore, despite any disadvantages that may arise in the process of displace drugs, the process remains the most effective of its kind in new-made times and hence plays a very important role in pharmaceutical question concerning future drug discovery.It is important to note that though most repurposed drugs have desirable pharmacokinetic and pharmacodynamics properties especially those that have passed various cl inical trial stages about 2000 of these drugs lie dormant of various companies shelves and Barratt and Frail (2012) suggest that this number grows at the rate of 150-200 drugs every year. Sequentially, this number creates more than equal substrate on which a repurposing strategy can be developed and as discontinued compounds are a by-product of carrying out line of reasoning in the pharmaceutical environment, there will never be a shortage of them. Hence, learning from these failures and applying the ever evolving science behind human biological science and diseases will not only salvage efforts made in the research and development environment but also lead to the development of a very viable business model while significantly change magnitude the risk of failure, cost of production and cycle time.BibliographySehkon, BS 2013, Repositioning drugs and biologics Retargeting old/existing drugs for potential new therapeutic applications, Journal Of Pharmaceutical instruction Resear ch, 4, 1, pp. 1-15, Academic Search Index, EBSCOhost, viewed 18 November 2014.Tari, L. B. and Patel J. H. (2014) online Systematic Drug Repurposing Through textbook Mining Biomedical Literature Mining vol. 1159, pp. 253-267 Available at http//www.springerprotocols.com/ overturn/doi/10.1007/978-1-4939-0709-0_14 Accessed 18th November, 2014Barratt, M. J. and Frail, D. E. (2012) Drug repositioning Bringing New sprightliness to Shelved Assets and Existing Drugs John Wiley Sons, Inc.Pantziarka, P., Bouche, G., Meheus, L.., Sukhatme, V., Sukhatme, V. P. (2014) online The Repurposing Drugs in Oncology (ReDO) Project ecancermedicalscience pp. 3 Available at http//ecancer.org/journal/8/full/442-the-repurposing-drugs-in-oncology-redo-project.php Accessed 17th November, 2014Persidis, A. (2011) online The benefits of drug repositioning Drug Discovery World Available at http//www.ddw-online.com/business/p142737-the-benefits-of-drug-repositioning-spring-11.html Accessed 17th November, 2014Tudor I. Oprea, Julie E. Bauman,Cristian G. Bologa, Tione Buranda, Alexandre Chigaev, Bruce S. Edwards, Jonathan W. Jarvik, Hattie D. Gresham,Mark K. Haynes,Brian Hjelle,Robert Hromas,Laurie Hudson,Debra A. Mackenzie,Carolyn Y. Muller,John C. Reed,Peter C. Simons,Yelena Smagley,Juan Strouse, Zurab Surviladze,Todd Thompson,Oleg Ursu,Anna Waller,Angela Wandinger-Ness,Stuart S. Winter,Yang Wu,Susan M. Young,Richard S. Larson,Cheryl Willman,andLarry A. Sklar (2012) online Drug repurposing from an academic perspective

No comments:

Post a Comment